GenesisCare, a provider of integrated cancer care globally, and Prelude Corporation (PreludeDxTM), a provider of molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes.
DCISionRT® is a precision medicine test for women diagnosed with DCIS (Ductal Carcinoma in situ) or Stage 0 breast cancer who are treated with breast-conserving surgery. The DCISionRT test, developed by PreludeDx, assesses a woman’s 10-year risk of recurrence of DCIS or development of invasive breast cancer. The test provides predictive information regarding recurrence risk, allowing physicians to better select those patients who will benefit from radiation therapy in addition to surgery.
Patients with DCIS have abnormal cells lining the milk ducts of the breast that have not spread into surrounding breast tissue. According to a March 2020 report from the National Center for Biotechnology Information in the United States, 20 percent of all breast carcinomas are DCIS.1 In Australia, women who are diagnosed with DCIS are, on average, 3.9 times more likely to develop invasive breast cancer than Australian women of a similar age without DCIS.2 With the help of DCISionRT, doctors are able to better identify patients with elevated scores and provide patients with information on whether receiving radiation therapy, in addition to surgery, will reduce the risk of DCIS recurrence or invasive disease.3
The new partnership between GenesisCare and PreludeDx will make DCISionRT testing available in Australia, where the test is currently not offered, as well as increase patient access in the United States through GenesisCare’s network of integrated cancer treatment centers. Australian-headquartered GenesisCare is one of the largest networks of integrated oncology care in the world, with more than 440 treatment centers and clinics across the US, Australia, the UK, and Spain.
Through the partnership GenesisCare and Prelude will also investigate the clinical development of precision medicine tests, for breast or other cancers, with global real-world evidence. GenesisCare will draw on its global network of physicians and clinical research expertise through its Contract Research Organization to extend Prelude’s existing US based registry to Australia to advance and further evaluate DCISionRT’s impact on treatment decision-making for women with DCIS.
GenesisCare’s Founder and Global Chief Executive Officer, Dan Collins, said: “GenesisCare is delighted to be bringing this much-needed test to early-stage breast cancer patients in Australia and the United States.”
“Over the last decade, we have witnessed the profound positive impact of precision medicine on the quality of life of cancer patients, through personalizing the therapeutic journey to an individual’s tumor and risk factors.”
“The innovative DCISionRT test heralds a new era in the delivery of precision cancer care, and we are thrilled to be at the forefront of bringing this latest evolution in personalized medicine to early-stage breast cancer patients around the globe.”
“Our new global partnership with PreludeDxTM will empower thousands of women with information about their own biological risk factors, enabling doctors and patients to make better-informed decisions about their treatment options,” said Mr. Collins.
PreludeDx’s President and Chief Executive Officer, Daniel Forche, said: “We share GenesisCare’s mission to treat every cancer patient as an individual and we are thrilled to be partnering with GenesisCare to increase patient access to DCISionRT.”
“This partnership is an important milestone as it means that for the first time, DCIS patients in Australia will have access to personalized information to better inform decisions about whether surgery alone or surgery with radiation therapy is appropriate.”
“This partnership will also leverage GenesisCare’s international network outside of the US to rapidly expand our real-world data registry and we are excited about the clinical evidence we will be able to provide to patients, physicians, governments and payers,” said Mr. Forche.
GenesisCare’s Global Chief Medical Officer, Dr. Wally Curran, said: “Historically, physicians have relied on clinical information and pathology to determine treatment plans for women with DCIS, but we can now employ molecular information from each patient’s cancer to personalize treatment plans with unrivaled confidence. We know that globally there are significant variations in the management of DCIS patients with radiotherapy in conjunction with surgery.”
“This test levels the diagnostic playing field for DCIS patients and will empower physicians and patients to make better-informed decisions about treatment options based on a patient’s individual biological risk profile,” said Dr. Curran.
References
- Vvan Seijen M., Lips E.H., Thompson A.M., Nik-Zainal S., Futreal A., Hwang E.S., Verschuur E., Lane J., Jonkers J., Rea D.W. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br. J. Cancer. 2019;121:285–292.
- Breast Cancer Network Australia 2020, Understanding breast cancer, What is breast cancer ductal carcinoma in situ, Breast Cancer Network Australia, accessed January 2021, < https://www.bcna.org.au/understanding-breast-cancer/what-is-breast-cancer/ductal-carcinoma-in-situ/?gclid=Cj0KCQiAlsv_BRDtARIsAHMGVSZ5BQ8E7lHCs5cz070rDBDsyNS5AT0yIn_EhEOBUuPjx2q6Fp2SR1YaAhtTEALw_wcB >
- Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995 March 15;75(6):1310-9. doi: 10.1002/1097-0142(19950315)75:6<1310::aid-cncr2820750613>3.0.co;2-g. PMID: 7882281.
